BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28447162)

  • 1. Cytomegalovirus retinitis in relapsed or refractory low-grade B cell lymphoma patients treated with bendamustine.
    Yamasaki S; Kohno K; Kadowaki M; Takase K; Iwasaki H
    Ann Hematol; 2017 Jul; 96(7):1215-1217. PubMed ID: 28447162
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytomegalovirus reactivation with bendamustine in patients with low-grade B-cell lymphoma.
    Hasegawa T; Aisa Y; Shimazaki K; Nakazato T
    Ann Hematol; 2015 Mar; 94(3):515-7. PubMed ID: 25107463
    [No Abstract]   [Full Text] [Related]  

  • 3. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
    Saito H; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto K; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Taniguchi H; Tobinai K
    Blood Cancer J; 2015 Oct; 5(10):e362. PubMed ID: 26495859
    [No Abstract]   [Full Text] [Related]  

  • 4. Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine.
    Isono N; Imai Y; Watanabe A; Moriya K; Tamura H; Inokuchi K; Asano C; Masuda M; Shimura H; Mitsuhashi K; Kazama H; Sugimori H; Motoji T; Tanaka J
    Leuk Lymphoma; 2016 Sep; 57(9):2204-7. PubMed ID: 26699798
    [No Abstract]   [Full Text] [Related]  

  • 5. [Development of cytomegalovirus antigenemia in 3 patients with B cell lymphoma treated with bendamustine monotherapy].
    Mitsumori T; Sueki Y; Kawashima I; Yamamoto T; Nozaki Y; Nakajima K; Kirito K
    Rinsho Ketsueki; 2014 Feb; 55(2):239-43. PubMed ID: 24598192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
    Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bendamustine can severely impair T-cell immunity against cytomegalovirus.
    Hosoda T; Yokoyama A; Yoneda M; Yamamoto R; Ohashi K; Kagoo T; Ueno H; Boku S; Yano T
    Leuk Lymphoma; 2013 Jun; 54(6):1327-8. PubMed ID: 23072371
    [No Abstract]   [Full Text] [Related]  

  • 8. Cytomegalovirus retinitis after intravitreal triamcinolone acetonide in an immunocompetent patient.
    Tetsuju S; Iida T; Kaneko H; Saito M
    Jpn J Ophthalmol; 2008; 52(5):414-416. PubMed ID: 18991048
    [No Abstract]   [Full Text] [Related]  

  • 9. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
    Howell M; Gibb A; Radford J; Linton K
    Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
    [No Abstract]   [Full Text] [Related]  

  • 10. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
    Munakata W; Tobinai K
    Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus Retinitis in a Human Immunodeficiency Virus-negative Cohort: Long-term Management and Complications.
    Jeon S; Lee WK
    Ocul Immunol Inflamm; 2015; 23(5):392-9. PubMed ID: 25760914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus.
    Kikuchi T; Mori T; Shimizu T; Koda Y; Abe R; Kurihara Y; Funakoshi T; Yamagami J; Sato H; Tsunoda K; Amagai M; Okamoto S
    Ann Hematol; 2017 Jul; 96(7):1221-1222. PubMed ID: 28447163
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir.
    Drew WL; Stempien MJ; Andrews J; Shadman A; Tan SJ; Miner R; Buhles W
    J Infect Dis; 1999 Jun; 179(6):1352-5. PubMed ID: 10228054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recommendation for the optimal use of bendamustine in Japan].
    Ohmachi K; Maruyama D; Nisikori M; Suzuki T; Izutsu K
    Rinsho Ketsueki; 2014 Mar; 55(3):311-20. PubMed ID: 24681934
    [No Abstract]   [Full Text] [Related]  

  • 15. Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma.
    Stöhr E; Schmeel FC; Schmeel LC; Hänel M; Schmidt-Wolf IG;
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2205-12. PubMed ID: 26156122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy with a combination of intravitreal foscarnet and intravenous ganciclovir in clinically resistant cytomegalovirus retinitis and patients with acquired immunodeficiency syndrome.
    Guembel HO; Hofmann F; van Even G; Cinatl J; Makabe R
    Ger J Ophthalmol; 1996 Nov; 5(6):490-1. PubMed ID: 9479542
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytomegalovirus antigenemia and end-organ disease in Japanese patients treated with bendamustine.
    Chiba A; Nakamura F; Nakazaki K; Kurokawa M
    Leuk Lymphoma; 2018 Mar; 59(3):749-751. PubMed ID: 28697686
    [No Abstract]   [Full Text] [Related]  

  • 18. Association of Soluble Interleukin-2 Receptor and C-Reactive Protein with the Efficacy of Bendamustine Salvage Treatment for Indolent Lymphomas and Mantle Cell Lymphoma.
    Kawaguchi Y; Nakamaki T; Abe M; Baba Y; Murai S; Watanuki M; Arai N; Fujiwara S; Kabasawa N; Tsukamoto H; Uto Y; Ariizumi H; Yanagisawa K; Hattori N; Harada H; Saito B
    Acta Haematol; 2018; 139(1):12-18. PubMed ID: 29301121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.
    Reboursiere E; Le Bras F; Herbaux C; Gyan E; Clavert A; Morschhauser F; Malak S; Sibon D; Broussais F; Braun T; Fornecker LM; Garidi R; Tricot S; Houot R; Joly B; Abarah W; Choufi B; Pham AD; Gac AC; Fruchart C; Marin E; Safar V; Parcelier A; Maisonneuve H; Bachy E; Cartron G; Jaccard A; Tournilhac O; Rossi C; Schirmer L; Martignoles JA; Gaulard P; Tilly H; Damaj G;
    Oncotarget; 2016 Dec; 7(51):85573-85583. PubMed ID: 27458168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcomes of reduced-dose intravitreal ganciclovir for cytomegalovirus retinitis.
    Choopong P; Vivittaworn K; Konlakij D; Thoongsuwan S; Pituksung A; Tesavibul N
    BMC Infect Dis; 2016 Apr; 16():164. PubMed ID: 27090644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.